Method of administering oxybate
US-2024398733-A1 · Dec 5, 2024 · US
US9320696B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9320696-B2 |
| Application number | US-201414505496-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 2, 2014 |
| Priority date | Dec 21, 2009 |
| Publication date | Apr 26, 2016 |
| Grant date | Apr 26, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Described herein are compositions comprising a MMP-13 inhibitor, and methods of using the same.
Opening claim text (preview).
What is claimed is: 1. A composition comprising a therapeutically effective amount of a MMP-13 inhibitor, and an orally acceptable carrier, wherein the MMP-13 inhibitor is 4-acetamidophenyl 2-isopropyl-5-methylcyclohexyl carbonate. 2. The composition of claim 1 , wherein the composition further comprises an MMP-13 inhibitor selected from the group consisting of cranberry extract non-dialyzable material, acetyl keto β-boswellic acid, resveratrol, and 2-isopropyl-5-methylcyclohexyl 2-hydroxyphenylcarbamate, and combinations thereof. 3. The composition of claim 2 , wherein the MMP-13 inhibitor comprises cranberry extract non-dialyzable material. 4. The composition of claim 2 , wherein the MMP-13 inhibitor comprises acetyl keto β-boswellic acid. 5. The composition of claim 2 , wherein the MMP-13 inhibitor comprises resveratrol. 6. The composition of claim 2 , wherein the MMP-13 inhibitor comprises 2-isopropyl-5-methylcyclohex 2-hydroxyphenylcarbamate. 7. The composition of claim 1 , wherein the composition is a dentifrice. 8. The composition of claim 7 , wherein the dentifrice is selected from the group consisting of: toothpaste; deep striped toothpaste; surface striped toothpaste; multi-layered toothpaste; a gel surrounding toothpaste; powder; beads; mouthwash; mouth rinses; lozenge; dental gel; a periodontal gel; a liquid suitable for painting a dental surface; a chewing gum; a dissolvable, partially dissolvable or non-dissolvable film or strip; a wafer; a wipe or towelette; an implant; a foam; a troche; a dental floss, liquid formulated for oral application in a small portable bottle; liquid formulated for oral application in a small portable drop-generating bottle; a soft pliable tablet; or a combination of two or more thereof.
Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis · CPC title
for bone diseases, e.g. rachitism, Paget's disease · CPC title
of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine · CPC title
Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) · CPC title
of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.